Services

Our services can be thought along a drugs life cycle and include strategic consulting and implementation of projects in the areas of pharmaceutical market access, reimbursement, HTA, and pricing in Germany—framed within a European and global corporate strategy.

AccessMatters

Project Impressions

2026

  • "Big Pharma": German Access Launch Scoping Assessment Hematology, multiple product & indications (HTA& price potential)

  • "Big Pharma": German team x-functional Workshop ATMP/cell-therapy launch readiness

  • "Big Pharma": German Price Negotiation validation & pre-arbitration biard situation check

  • "Consultancy": Providing German expertise in G-BA Consultation with international client immunology

  • "Consultancy": Sounding board access & pricing pathway cardiovascular

  • "Academics": ISPOR Poster on German Market Access specific Pricing Analysis

  • "Biotech": (>6 months, ongoing): Interim Market Access & Pricing

  • "Big Pharma": (>6 months, ongoing): Interim Market Access & Pricing